With more than 200 different cell types in the human body, a key goal of Cellular Dynamics International (CDI), a Fujifilm company, is to continue to expand the portfolio of available human iPSC-derived tissues where possible and where there is a scientific need. For example, CDI’s first-generation GABAergic iCell Neurons are inhibitory cortical neurons that recapitulate many features of human neurons. The utility of this cell type was immediately demonstrated as an alternative model to primary animal-based neuronal preparations for assessing neurite outgrowth as well as developmental and general neuronal cytotoxicity. However, as they are a primarily inhibitory neuronal population, they provided limited utility for assessing networked neuronal electrical activity. [Read more…]
Recently, I had the honor of interviewing Kaz Hirao, CEO of Cellular Dynamics International (CDI), the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI recently divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics. As featured in the company motto, CDI is now positioned to facilitate “Endless Possibilities from Discovery to Regenerative Medicine.”
While a number of companies have dabbled in this space, the following players are facilitating the development of iPS cell therapies: Cellular Dynamics International (CDI), Cynata Therapeutics, RIKEN, and Astellas (previously Ocata Therapeutics).
While each iPS cell therapy group is considered in detail below, Cellular Dynamics International (CDI) is featured first, because it dominates the iPSC industry. CDI also recently split into two business units, a Life Science Unit and a Therapeutics Unit, demonstrating a commercial strategy for its iPS cell therapy development. [Read more…]
We have released coverage of this week’s stem cell industry activity that I am excited to share with you. It was a major week for stem cells, with CDI launching Opsis Therapeutics, Provia Laboratories expanding its stem cell product portfolio, CCBC getting a FDA Biologics License for CLEVECORD™, STEMCELL Technologies exploring genomic instability in an upcoming webinar, and iPSCs turning 10. [Read more…]
MADISON, WIS, September 28, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company and the leading developer and manufacturer of induced pluripotent stem cell (iPSC) products, today announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases. [Read more…]